Evaluating Novel Formulations and Emerging Agents in the Management of Acute Myeloid Leukemia: Enhancing Outcomes, Tolerability, and Access

Evaluating Novel Formulations and Emerging Agents in the Management of Acute Myeloid Leukemia: Enhancing Outcomes, Tolerability, and Access

On-Demand Webcast

William J. Cardarelli, PharmD
Director of Pharmacy Revenue and Supply
Atrius Health
Harvard Vanguard Medical Associates
Watertown, Massachusetts

Joseph G. Jurcic, MD
Professor of Medicine
Division of Hematology/Oncology
Director of the Hematologic Malignancies Section
Columbia University Medical Center
Attending Physician
New York Presbyterian Hospital
Herbert Irving Comprehensive Cancer Center
New York, New York

Intended Learners

This activity is designed for pharmacy directors, medical directors, and other decision makers working in managed care organizations.

Learning Objectives

After completing this activity, participants should be able to:

  • Quantify  the  clinical  and  economic  burden  of  AML,  including  factors  that  contribute  to  poor prognosis and increased costs
  • Highlight the limitations of current AML treatments in terms of survival, tolerability, quality of life, hospitalizations, and utilization
  • Review the impact of intensive treatment initiation for AML in older populations
  • Evaluate  the  clinical  and  pharmacoeconomic  profiles  of  novel  chemotherapeutic  formulations and targeted agents
  • Leverage  therapeutic  advances  and  resource  utilization  data  into  informed  plan  decisions  and formulary discussions
Activity Overview

To be eligible for documentation of credit, participants must complete the educational activity, complete the 10 question post-test with a score of 70% or better, and complete the evaluation form.

After successful completion of the post-test and evaluation form online at www.naccme.com, participants may immediately print their documentation of credit.

ACPE Credit Policy

The certificate is not the official record of your participation in the activity. The official record of credit will be the information in CPE Monitor system.

Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended. The reporting function into CPE Monitor will only be available for 60 days after your completion of the activity.  Under ACPE Policy, NACCME will not be able to report your credit to CPE Monitor after this 60 day period.

Release Date: October 23, 2017
Expiration Date: October 23, 2018
Estimated time to complete: 1 hour

Participants who completed the live version of this activity are not eligible to receive credit for this enduring material.

For questions regarding this educational activity, please call 609-371-1137.

There is no fee associated with this activity.

Hardware/Software Requirements

All educational activities are accessible via a PC (Windows 2000/XP/Vista/7) or Mac (Mac OS 10.x or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. Windows Media Player or compatible alternative, sound card, and speakers are required for streamed audio. The latest version of the Adobe Flash Player is suggested for video programs (please download here). A PDF reader is required for print publications. Please direct technical questions to webmaster@naccme.com.


    In support of improving patient care, North American Center for Continuing Medical Education (NACCME) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.



NACCME designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This enduring activity is approved for 1.0 contact hour (.1 CEUs) of continuing pharmacy education (JA0006201-0000-18-121-H01-P).

This educational activity is a knowledge-based activity.

Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity accredited by NACCME may contact the Senior Manager, Accreditation & Compliance, NACCME, in writing at 104 Windsor Center Drive, East Windsor, NJ 08520. The Senior Manager, Accreditation & Compliance will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Senior Director, Accreditation and Compliance, NACCME, may be made for a second level of review.

Independent Clinical Reviewer: Elias Joseph Jabbour, MD, Associate Professor, Department of Leukemia, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas

Planning Committee

The planning committee comprises William J. Cardarelli, PharmD, Elias Joseph Jabbour, MD, Joseph G. Jurcic, MD; and Donna Brophy, Kristin Ciszeski, Mary Johnson, Michael Kearney, Susan Kuhn, Michelle Montgomery, Randy Robbin, John Savage, and Sydney Turner, NACCME.

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

Dr. Jurcic: Research FundingActinium Pharmaceuticals, Inc., Astellas Pharma, Celgene, Daiichi Sankyo, Forma Therapeutics, Genentech, Kura Oncology, Seattle Genetics, Inc., Syros Pharmaceuticals; Advisory BoardIncyte; Independent Review CommitteeNovartis

Dr. Cardarelli and Dr. Jabbour have disclosed no relevant financial relationships with any commercial interest.

Ms. Brophy, Ms. Ciszeski, Ms. Johnson, Mr. Kearney, Ms. Montgomery, Mr. Robbin, Mr. Savage and Ms. Turner have disclosed no relevant financial relationships with any commercial interests.

Ms. Kuhn: Stock Shareholder (spouse)—Osiris Pharmaceuticals

NACCME requires faculty to inform participants whenever off-label/unapproved uses of drugs and/or devices are discussed in their presentations.

The faculty have disclosed that the off-label/unapproved use of CPX-351 for older patients with high-risk AML; quizartinib, gilteritinib, and crenolanib for FLT3-mutated AML; enasidenib (AG-221) for relapsed/refractory IDH2-mutated AML; and venetoclax, vadastuximab talirine, Actinium-225-lintuzumab for older AML patients not eligible for intensive chemotherapy will be discussed in the presentation.

Privacy Policy

NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME and our joint sponsors will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2017 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education. The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.

Grant Support

This activity is supported by an educational grant from Jazz Pharmaceuticals, Inc.